Success Metrics

Clinical Success Rate
82.4%

Based on 14 completed trials

Completion Rate
82%(14/17)
Active Trials
9(26%)
Results Posted
71%(10 trials)
Terminated
3(9%)

Phase Distribution

Ph phase_2
13
38%
Ph phase_1
12
35%
Ph phase_3
2
6%
Ph not_applicable
3
9%
Ph early_phase_1
4
12%

Phase Distribution

16

Early Stage

13

Mid Stage

2

Late Stage

Phase Distribution34 total trials
Early Phase 1First-in-human
4(11.8%)
Phase 1Safety & dosage
12(35.3%)
Phase 2Efficacy & side effects
13(38.2%)
Phase 3Large-scale testing
2(5.9%)
N/ANon-phased studies
3(8.8%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

70.0%

14 of 20 finished

Non-Completion Rate

30.0%

6 ended early

Currently Active

9

trials recruiting

Total Trials

34

all time

Status Distribution
Active(9)
Completed(14)
Terminated(6)
Other(5)

Detailed Status

Completed14
Recruiting5
unknown5
Active, not recruiting4
Terminated3
Withdrawn3

Development Timeline

Analytics

Development Status

Total Trials
34
Active
9
Success Rate
82.4%
Most Advanced
Phase 3

Trials by Phase

Early Phase 14 (11.8%)
Phase 112 (35.3%)
Phase 213 (38.2%)
Phase 32 (5.9%)
N/A3 (8.8%)

Trials by Status

recruiting515%
active_not_recruiting412%
unknown515%
terminated39%
withdrawn39%
completed1441%

Recent Activity

Clinical Trials (34)

Showing 20 of 34 trialsScroll for more
NCT02379520Phase 1

HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA

Completed
NCT06692452Phase 2

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Withdrawn
NCT04224558Phase 1

Stem Cell Transplantation in Crohn's Disease

Recruiting
NCT01203722Phase 1

Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies

Completed
NCT06528496Phase 2

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

Recruiting
NCT06409390Phase 2

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Recruiting
NCT02932956Phase 1

Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)

Active Not Recruiting
NCT01192555Phase 1

Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma

Active Not Recruiting
NCT04715191Phase 1

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

Recruiting
NCT02905188Phase 1

Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)

Completed
NCT01822652Phase 1

3rd Generation GD-2 Chimeric Antigen Receptor and ICaspase Suicide Safety Switch, Neuroblastoma, GRAIN

Active Not Recruiting
NCT04713371Phase 2

A Phase 2 Trial for Patients With Metastatic Solid Cancer

Active Not Recruiting
NCT02995330Phase 1

Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer

Terminated
NCT00950846Not Applicable

Umbilical Cord Blood Transplant for Congenital Pediatric Disorders

Completed
NCT05936086Not Applicable

A Randomized Controlled Study of High-dose Cyclophosphamide Induction Therapy in Adult Patients With HLH

Recruiting
NCT00496873Phase 2

Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan

Completed
NCT04090775Phase 2

A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma

Completed
NCT05008575Phase 1

Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Unknown
NCT05008536Early Phase 1

Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma

Unknown
NCT05016063Early Phase 1

Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Unknown

Drug Details

Intervention Type
DRUG
Total Trials
34